<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2199">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04345289</url>
  </required_header>
  <id_info>
    <org_study_id>25032020</org_study_id>
    <secondary_id>2020-001367-88</secondary_id>
    <nct_id>NCT04345289</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia</brief_title>
  <acronym>CCAP</acronym>
  <official_title>Efficacy and Safety of Treatment With Convalescent Plasma for Adults With COVID-19 Pneumonia. A Double-blinded, Randomized, Multicenter Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Benfield</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hvidovre University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      CCAP is an investigator-initiated multicentre, randomized, double blinded, placebo-controlled
      trial, which aims to assess the safety and efficacy of treatment with convalescent plasma for
      patients with moderate-severe COVID-19.

      Participants will be randomized 2:1 to two parallel treatment arms: Convalescent plasma, and
      intravenous placebo.

      Primary outcome is a composite endpoint of all-cause mortality or need of invasive mechanical
      ventilation up to 28 days.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a randomized, double blinded, placebo-controlled, multicenter study with two
      parallel treatment arms consisting of either convalescent plasma or intravenous placebo. We
      plan to enroll a total of 1100 patients yielding a statistical power of 80 % to show a 30%
      relative reduction in risk of mechanical ventilation or death at day 28. Patients with
      confirmed COVID-19 infection and signs compatible with pneumonia will be enrolled in the
      study. The participants will be randomized 2:1 to the parallel treatment arms, and receive
      either single dose infusion treatment.

      The primary outcome is a composite endpoint of all-cause mortality or need of invasive
      mechanical ventilation up to 28 days. Interim analysis will be performed frequently.

      As new knowledge of treatment options for COVID-19 have emerged, the treatment arms including
      sarilumab, baricitininb, hydroxychloroquine and oral placebo have been terminated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2020</start_date>
  <completion_date type="Anticipated">June 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Adaptive multi-arm trial comparing convalescent plasma against control group. Interim analyses are included at 300 and 700 included participants to compare the effect and safety of the experimental treatment to control (placebo). The results of the interim analyses are used to decide if the treatments should be discontinued due to either futility or harm. The study is discontinued if either of the predefined stopping criteria are met.
Additional experimental treatments may be added as they become available. Any efficacious treatment identified in this or any other high-quality RCT may become the new SOC after consensus by national and international societies, and, thus, the control arm will change accordingly and in parallel.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Both convalescent plasma and placebo will be administered via a colored intravenous line with a colored sleeve disguising the fluid bag.
In order to achieve blinding of participants and treating personnel, patients randomized to active treatment will also receive placebo treatment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality or need of invasive mechanical ventilation</measure>
    <time_frame>28 days</time_frame>
    <description>Composite outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse events</measure>
    <time_frame>90 days</time_frame>
    <description>Number of participants with adverse events with possible relation to study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of severe adverse events</measure>
    <time_frame>90 days</time_frame>
    <description>Number of participants with serious adverse events according to International Council of Harmonisation-Good Clinical Practice (ICH-GCP) guidelines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to improvement of at least 2 categories relative to baseline on a 7-category ordinal scale of clinical status</measure>
    <time_frame>90 days</time_frame>
    <description>Number of days to improvement of at least 2 categories relative to baseline on the ordinal scale. Categories are as follows: Death; Hospitalized, in intensive care requiring Extracorporeal Membrane Oxygenation (ECMO) or mechanical ventilation; Hospitalized, on non-invasive ventilation or high-flow oxygen device; Hospitalized, requiring supplemental oxygen; Hospitalized, not requiring supplemental oxygen; Not hospitalized, limitation on activities and/or requiring home oxygen; Not hospitalized, no limitations on activities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator-free days</measure>
    <time_frame>28 days</time_frame>
    <description>Number of days without mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organ failure-free days</measure>
    <time_frame>28 days</time_frame>
    <description>Number of days without organ-failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of ICU stay</measure>
    <time_frame>90 days</time_frame>
    <description>Number of days in ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>7, 14, 21, 28 and 90 days</time_frame>
    <description>Number of deaths by any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>90 days</time_frame>
    <description>Days from the date of hospital admission for COVID-19 to the date of discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of supplemental oxygen</measure>
    <time_frame>90 days</time_frame>
    <description>Days requiring supplement oxygen</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1100</enrollment>
  <condition>COVID</condition>
  <condition>Corona Virus Infection</condition>
  <condition>Viral Pneumonia</condition>
  <arm_group>
    <arm_group_label>Convalescent plasma</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Will receive active treatment with convalescent anti-SARS-CoV-2 plasma (600 ml) as a single dose iv infusion in addition to standard care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infusion placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Will receive placebo treatment with saline 0.9% (2 x 300 ml) as an iv single dose infusion in addition to standard care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Convalescent anti-SARS-CoV-2 plasma</intervention_name>
    <description>Single infusion of convalescent anti-SARS-CoV-2 plasma (2 x 300 mL)</description>
    <arm_group_label>Convalescent plasma</arm_group_label>
    <other_name>Convalescent plasma</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Infusion placebo</intervention_name>
    <description>Saline 0.9% (600 ml) as an iv single dose infusion</description>
    <arm_group_label>Infusion placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥18 years of age

          -  Confirmed COVID-19 infection by presence of SARS-CoV-2 nucleic acid by polymerase
             chain reaction (PCR)

          -  Evidence of pneumonia given by at least one of the following: SpO2 ≤93% on ambient air
             or PaO2/FiO2 &lt;300 mmHg/40 kPa OR Radiographic findings compatible with COVID-19
             pneumonia

          -  For women of childbearing potential: Negative pregnancy test and willingness to use
             contraceptive (consistent with local regulations) during study period

          -  Signed Informed Consent Form by any patient capable of giving consent, or, when the
             patient is not capable of giving consent, by his or her legal/authorized
             representatives

        Exclusion Criteria:

          -  In the opinion of the investigator, progression to death is imminent and inevitable
             within the next 24 hours, irrespective of the provision of treatment

          -  Participating in other drug clinical trials (participation in COVID-19 antiviral
             trials may be permitted if approved by sponsor)*

          -  Pregnant or breastfeeding, positive pregnancy test in a pre-dose examination

          -  Any serious medical condition or abnormality of clinical laboratory tests that, in the
             investigator's judgment, precludes the patient's safe participation in and completion
             of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandra Hansen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hvidovre University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Simone Bastrup Israelsen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hvidovre University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Louise Thorlacius-Ussing, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hvidovre University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karen Brorup Heje Pedersen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hvidovre University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Clara Clausen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hvidovre University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michaela Tinggaard, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hvidovre University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nichlas Hovmand, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hvidovre University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas Benfield, MD, DMSc</last_name>
    <phone>+45 38622302</phone>
    <email>thomas.lars.benfield@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Henrik Nielsen, MD, DMSc</last_name>
    </contact>
    <contact_backup>
      <email>henrik.nielsen@rn.dk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Arhus</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lars Østergaard, MD, DMSc</last_name>
    </contact>
    <contact_backup>
      <email>larsoest@rm.dk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stine Johnsen, MD, PhD</last_name>
      <email>stine.johnsen.01@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jan Gerstoft, MD, DMSc</last_name>
    </contact>
    <contact_backup>
      <email>jan.gerstoft@regionh.dk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Herlev Gentofte Hospital</name>
      <address>
        <city>Herlev</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kasper Iversen, MD, DMSc</last_name>
      <email>kasper.karmark.iversen@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herning Hospital</name>
      <address>
        <city>Herning</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rajesh Mohey, MD, PhD</last_name>
      <email>rajemohe@rm.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nordsjællands Hospital</name>
      <address>
        <city>Hillerød</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Birgitte Lindegaard Madsen, MD, PhD</last_name>
      <email>birgitte.lindegaard.madsen@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hvidovre Hospital</name>
      <address>
        <city>Hvidovre</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Benfield, MD, DMSc</last_name>
      <phone>+4538622302</phone>
      <email>thomas.lars.benfield@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kolding Hospital</name>
      <address>
        <city>Kolding</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Janne Jensen, MD, PhD</last_name>
      <email>janne.jensen@rsyd.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isik Johansen, MD, DMSc</last_name>
      <email>isik.somuncu.johansen@rsyd.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Roskilde Hospital</name>
      <address>
        <city>Roskilde</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lothar Wiese, MD, PhD</last_name>
      <email>low@regionsjaelland.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vejle Hospital</name>
      <address>
        <city>Vejle</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ole Hilberg, MD, DMSc</last_name>
      <email>ole.hilberg@rsyd.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>World Health Organization. Coronavirus disease 2019 (COVID-19) - Situation Report 67. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200327-sitrep-67-covid-19.pdf?sfvrsn=b65f68eb_4.</citation>
  </reference>
  <reference>
    <citation>Cameron MJ, Bermejo-Martin JF, Danesh A, Muller MP, Kelvin DJ. Human immunopathogenesis of severe acute respiratory syndrome (SARS). Virus Res. 2008 Apr;133(1):13-9. Epub 2007 Mar 19.</citation>
    <PMID>17374415</PMID>
  </reference>
  <reference>
    <citation>Matthay MA, Ware LB, Zimmerman GA. The acute respiratory distress syndrome. J Clin Invest. 2012 Aug;122(8):2731-40. doi: 10.1172/JCI60331. Epub 2012 Aug 1. Review.</citation>
    <PMID>22850883</PMID>
  </reference>
  <reference>
    <citation>Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017 Jul;39(5):529-539. doi: 10.1007/s00281-017-0629-x. Epub 2017 May 2. Review.</citation>
    <PMID>28466096</PMID>
  </reference>
  <reference>
    <citation>Li Y, Chen M, Cao H, Zhu Y, Zheng J, Zhou H. Extraordinary GU-rich single-strand RNA identified from SARS coronavirus contributes an excessive innate immune response. Microbes Infect. 2013 Feb;15(2):88-95. doi: 10.1016/j.micinf.2012.10.008. Epub 2012 Oct 30.</citation>
    <PMID>23123977</PMID>
  </reference>
  <reference>
    <citation>Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, Li X, Xia J, Chen N, Xiang J, Yu T, Bai T, Xie X, Zhang L, Li C, Yuan Y, Chen H, Li H, Huang H, Tu S, Gong F, Liu Y, Wei Y, Dong C, Zhou F, Gu X, Xu J, Liu Z, Zhang Y, Li H, Shang L, Wang K, Li K, Zhou X, Dong X, Qu Z, Lu S, Hu X, Ruan S, Luo S, Wu J, Peng L, Cheng F, Pan L, Zou J, Jia C, Wang J, Liu X, Wang S, Wu X, Ge Q, He J, Zhan H, Qiu F, Guo L, Huang C, Jaki T, Hayden FG, Horby PW, Zhang D, Wang C. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020 May 7;382(19):1787-1799. doi: 10.1056/NEJMoa2001282. Epub 2020 Mar 18.</citation>
    <PMID>32187464</PMID>
  </reference>
  <reference>
    <citation>Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020 Mar 16;14(1):72-73. doi: 10.5582/bst.2020.01047. Epub 2020 Feb 19.</citation>
    <PMID>32074550</PMID>
  </reference>
  <reference>
    <citation>Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. doi: 10.1038/s41422-020-0282-0. Epub 2020 Feb 4.</citation>
    <PMID>32020029</PMID>
  </reference>
  <reference>
    <citation>Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020 May;55(5):105938. doi: 10.1016/j.ijantimicag.2020.105938. Epub 2020 Mar 12.</citation>
    <PMID>32171740</PMID>
  </reference>
  <reference>
    <citation>Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med. 2006 Oct 17;145(8):599-609. Epub 2006 Aug 29.</citation>
    <PMID>16940336</PMID>
  </reference>
  <reference>
    <citation>Hung IF, To KK, Lee CK, Lee KL, Chan K, Yan WW, Liu R, Watt CL, Chan WM, Lai KY, Koo CK, Buckley T, Chow FL, Wong KK, Chan HS, Ching CK, Tang BS, Lau CC, Li IW, Liu SH, Chan KH, Lin CK, Yuen KY. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011 Feb 15;52(4):447-56. doi: 10.1093/cid/ciq106. Epub 2011 Jan 19.</citation>
    <PMID>21248066</PMID>
  </reference>
  <reference>
    <citation>Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, Lim WS, Makki S, Rooney KD, Nguyen-Van-Tam JS, Beck CR; Convalescent Plasma Study Group. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015 Jan 1;211(1):80-90. doi: 10.1093/infdis/jiu396. Epub 2014 Jul 16. Review.</citation>
    <PMID>25030060</PMID>
  </reference>
  <reference>
    <citation>Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen Morales L, Reyes Gonzaga J, Yakushin S, Ishii T, Emoto K, Beattie S, Arora V, Gaich C, Rooney T, Schlichting D, Macias WL, de Bono S, Tanaka Y. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med. 2017 Feb 16;376(7):652-662. doi: 10.1056/NEJMoa1608345.</citation>
    <PMID>28199814</PMID>
  </reference>
  <reference>
    <citation>Wu D, Yang XO. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib. J Microbiol Immunol Infect. 2020 Jun;53(3):368-370. doi: 10.1016/j.jmii.2020.03.005. Epub 2020 Mar 11.</citation>
    <PMID>32205092</PMID>
  </reference>
  <reference>
    <citation>Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D, Richardson P. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020 Apr;20(4):400-402. doi: 10.1016/S1473-3099(20)30132-8. Epub 2020 Feb 27.</citation>
    <PMID>32113509</PMID>
  </reference>
  <reference>
    <citation>Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest. 2020 Apr 1;130(4):1545-1548. doi: 10.1172/JCI138003.</citation>
    <PMID>32167489</PMID>
  </reference>
  <reference>
    <citation>Cunningham AC, Goh HP, Koh D. Treatment of COVID-19: old tricks for new challenges. Crit Care. 2020 Mar 16;24(1):91. doi: 10.1186/s13054-020-2818-6.</citation>
    <PMID>32178711</PMID>
  </reference>
  <reference>
    <citation>Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH, Chan P, Wong KC, Leung CB, Cheng G. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005 Jan;24(1):44-6.</citation>
    <PMID>15616839</PMID>
  </reference>
  <reference>
    <citation>Soo YO, Cheng Y, Wong R, Hui DS, Lee CK, Tsang KK, Ng MH, Chan P, Cheng G, Sung JJ. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect. 2004 Jul;10(7):676-8.</citation>
    <PMID>15214887</PMID>
  </reference>
  <reference>
    <citation>Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, Wang F, Li D, Yang M, Xing L, Wei J, Xiao H, Yang Y, Qu J, Qing L, Chen L, Xu Z, Peng L, Li Y, Zheng H, Chen F, Huang K, Jiang Y, Liu D, Zhang Z, Liu Y, Liu L. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA. 2020 Apr 28;323(16):1582-1589. doi: 10.1001/jama.2020.4783.</citation>
    <PMID>32219428</PMID>
  </reference>
  <reference>
    <citation>Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, Yu J, Kang M, Song Y, Xia J, Guo Q, Song T, He J, Yen HL, Peiris M, Wu J. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. N Engl J Med. 2020 Mar 19;382(12):1177-1179. doi: 10.1056/NEJMc2001737. Epub 2020 Feb 19.</citation>
    <PMID>32074444</PMID>
  </reference>
  <reference>
    <citation>Zhang Y, Li J, Zhan Y, Wu L, Yu X, Zhang W, Ye L, Xu S, Sun R, Wang Y, Lou J. Analysis of serum cytokines in patients with severe acute respiratory syndrome. Infect Immun. 2004 Aug;72(8):4410-5.</citation>
    <PMID>15271897</PMID>
  </reference>
  <reference>
    <citation>Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb 15;395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7. Epub 2020 Jan 30.</citation>
    <PMID>32007143</PMID>
  </reference>
  <reference>
    <citation>Pelechas E, Voulgari PV, Drosos AA. Clinical evaluation of the safety, efficacy and tolerability of sarilumab in the treatment of moderate to severe rheumatoid arthritis. Ther Clin Risk Manag. 2019 Sep 4;15:1073-1079. doi: 10.2147/TCRM.S167452. eCollection 2019.</citation>
    <PMID>31564885</PMID>
  </reference>
  <reference>
    <citation>Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, Seidah NG, Nichol ST. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005 Aug 22;2:69.</citation>
    <PMID>16115318</PMID>
  </reference>
  <reference>
    <citation>Klumperman J, Locker JK, Meijer A, Horzinek MC, Geuze HJ, Rottier PJ. Coronavirus M proteins accumulate in the Golgi complex beyond the site of virion budding. J Virol. 1994 Oct;68(10):6523-34.</citation>
    <PMID>8083990</PMID>
  </reference>
  <reference>
    <citation>Gay B, Bernard E, Solignat M, Chazal N, Devaux C, Briant L. pH-dependent entry of chikungunya virus into Aedes albopictus cells. Infect Genet Evol. 2012 Aug;12(6):1275-81. doi: 10.1016/j.meegid.2012.02.003. Epub 2012 Feb 20.</citation>
    <PMID>22386853</PMID>
  </reference>
  <reference>
    <citation>multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia. [Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia]. Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):185-188. doi: 10.3760/cma.j.issn.1001-0939.2020.03.009. Chinese.</citation>
    <PMID>32164085</PMID>
  </reference>
  <reference>
    <citation>Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Tissot Dupont H, Honoré S, Colson P, Chabrière E, La Scola B, Rolain JM, Brouqui P, Raoult D. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.</citation>
    <PMID>32205204</PMID>
  </reference>
  <reference>
    <citation>Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Liu X, Zhao L, Dong E, Song C, Zhan S, Lu R, Li H, Tan W, Liu D. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020 Jul 28;71(15):732-739. doi: 10.1093/cid/ciaa237.</citation>
    <PMID>32150618</PMID>
  </reference>
  <reference>
    <citation>Jaki T, Wason JMS. Multi-arm multi-stage trials can improve the efficiency of finding effective treatments for stroke: a case study. BMC Cardiovasc Disord. 2018 Nov 27;18(1):215. doi: 10.1186/s12872-018-0956-4.</citation>
    <PMID>30482176</PMID>
  </reference>
  <reference>
    <citation>Cordon-Cardo C, Lloyd KO, Finstad CL, McGroarty ME, Reuter VE, Bander NH, Old LJ, Melamed MR. Immunoanatomic distribution of blood group antigens in the human urinary tract. Influence of secretor status. Lab Invest. 1986 Oct;55(4):444-54.</citation>
    <PMID>2429066</PMID>
  </reference>
  <reference>
    <citation>Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, Reinhart CK, Suter PM, Thijs LG. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996 Jul;22(7):707-10.</citation>
    <PMID>8844239</PMID>
  </reference>
  <reference>
    <citation>Distler P. ISBT 128: a global information standard. Cell Tissue Bank. 2010 Nov;11(4):365-73. doi: 10.1007/s10561-010-9196-2. Epub 2010 Jul 21.</citation>
    <PMID>20652420</PMID>
  </reference>
  <reference>
    <citation>Clegg DO, Dietz F, Duffy J, Willkens RF, Hurd E, Germain BF, Wall B, Wallace DJ, Bell CL, Sleckman J. Safety and efficacy of hydroxychloroquine as maintenance therapy for rheumatoid arthritis after combination therapy with methotrexate and hydroxychloroquine. J Rheumatol. 1997 Oct;24(10):1896-902.</citation>
    <PMID>9330929</PMID>
  </reference>
  <reference>
    <citation>Middelburg RA, Van Stein D, Zupanska B, Uhrynowska M, Gajic O, Muñiz-Diaz E, Galvez NN, Silliman CC, Krusius T, Wallis JP, Vandenbroucke JP, Briët E, Van Der Bom JG. Female donors and transfusion-related acute lung injury: A case-referent study from the International TRALI Unisex Research Group. Transfusion. 2010 Nov;50(11):2447-54. doi: 10.1111/j.1537-2995.2010.02715.x.</citation>
    <PMID>20529001</PMID>
  </reference>
  <reference>
    <citation>Lamb YN, Deeks ED. Sarilumab: A Review in Moderate to Severe Rheumatoid Arthritis. Drugs. 2018 Jun;78(9):929-940. doi: 10.1007/s40265-018-0929-z. Review.</citation>
    <PMID>29931592</PMID>
  </reference>
  <reference>
    <citation>Pocock SJ, Ariti CA, Collier TJ, Wang D. The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. Eur Heart J. 2012 Jan;33(2):176-82. doi: 10.1093/eurheartj/ehr352. Epub 2011 Sep 6.</citation>
    <PMID>21900289</PMID>
  </reference>
  <reference>
    <citation>Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585.</citation>
    <PMID>32031570</PMID>
  </reference>
  <reference>
    <citation>Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, Villamizar-Peña R, Holguin-Rivera Y, Escalera-Antezana JP, Alvarado-Arnez LE, Bonilla-Aldana DK, Franco-Paredes C, Henao-Martinez AF, Paniz-Mondolfi A, Lagos-Grisales GJ, Ramírez-Vallejo E, Suárez JA, Zambrano LI, Villamil-Gómez WE, Balbin-Ramon GJ, Rabaan AA, Harapan H, Dhama K, Nishiura H, Kataoka H, Ahmad T, Sah R; Latin American Network of Coronavirus Disease 2019-COVID-19 Research (LANCOVID-19). Electronic address: https://www.lancovid.org. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis. 2020 Mar - Apr;34:101623. doi: 10.1016/j.tmaid.2020.101623. Epub 2020 Mar 13.</citation>
    <PMID>32179124</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 10, 2020</study_first_submitted>
  <study_first_submitted_qc>April 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2020</study_first_posted>
  <last_update_submitted>July 29, 2020</last_update_submitted>
  <last_update_submitted_qc>July 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hvidovre University Hospital</investigator_affiliation>
    <investigator_full_name>Thomas Benfield</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Pneumonia, Viral</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

